Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
Sponsor: Huai'an First People's Hospital
Summary
This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA(Venetoclax with Homoharringtonine,Etoposide,Cytarabine)regimen in the treatment of newly diagnosed and relapsed/refractory acute myeloid leukemia (AML) with MLL gene abnormalities. This study includes the induction and consolidation phases of AML treatment.
Official title: Clinical Study Protocol for the Treatment of Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia With KMT2A Gene Abnormalities Using VHEA(Venetoclax With Homoharringtonine,Etoposide,Cytarabine)
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
34
Start Date
2022-05-24
Completion Date
2027-12-30
Last Updated
2024-03-25
Healthy Volunteers
No
Conditions
Interventions
Venetoclax 100 mg d1,200 mg d2,400 mg d3-14;
VHEA -Induction Phase Regimen/Consolidation therapy after remission
Locations (1)
The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University(Huai'an First People's Hospital)
Huai'an, Jiangsu, China